Investment analysts at Wedbush initiated coverage on shares of Crescent Biopharma (NASDAQ:CBIO - Get Free Report) in a research note issued on Monday, Marketbeat.com reports. The firm set an "outperform" rating and a $27.00 price target on the biopharmaceutical company's stock. Wedbush's target price points to a potential upside of 110.94% from the stock's current price.
A number of other research firms have also commented on CBIO. Wall Street Zen upgraded shares of Crescent Biopharma to a "sell" rating in a research note on Saturday. TD Cowen raised Crescent Biopharma to a "strong-buy" rating in a research note on Friday, June 20th. Stifel Nicolaus started coverage on Crescent Biopharma in a research note on Wednesday, June 25th. They issued a "buy" rating and a $28.00 target price on the stock. Finally, Lifesci Capital raised Crescent Biopharma to a "strong-buy" rating and set a $22.00 target price on the stock in a report on Wednesday, June 18th. One analyst has rated the stock with a sell rating, two have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and an average target price of $25.67.
Read Our Latest Research Report on CBIO
Crescent Biopharma Trading Down 1.2%
Shares of CBIO traded down $0.16 during mid-day trading on Monday, reaching $12.80. 140,271 shares of the company's stock were exchanged, compared to its average volume of 30,593. The firm has a market cap of $250.24 million, a PE ratio of -0.28 and a beta of 1.52. Crescent Biopharma has a 52-week low of $11.06 and a 52-week high of $63.00.
About Crescent Biopharma
(
Get Free Report)
Crescent Biopharma, Inc operates as a biopharmaceutical company that develops and designs small molecule therapeutics to treat cancers. The company was founded on September 19, 2024 and is headquartered in Waltham, MA.
Read More
Before you consider Crescent Biopharma, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Crescent Biopharma wasn't on the list.
While Crescent Biopharma currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
